R. Fox

发表

Prevention of cyclophosphamide-induced and spontaneous diabetes in NOD mice by syngeneic splenocytes treated with cytotoxic drugs.

D. Marks, M. Coote, B. Iannoni, 1991, Autoimmunity.

Extracorporeal photochemotherapy in the treatment of cutaneous T-cell lymphoma. Complexity of objective evaluation.

G. Varigos, S. Rockman, M. Green, 1991, International journal of dermatology.

Mechanisms of photochemotherapy-induced apoptotic cell death in lymphoid cells.

D. Marks, R. Fox, 1991, Biochemistry and cell biology = Biochimie et biologie cellulaire.

Mechanisms of lymphocytotoxicity induced by extracorporeal photochemotherapy for cutaneous T cell lymphoma.

S. Rockman, D. Marks, R. Fox, 1990, The Journal of clinical investigation.

S-adenosylhomocysteine hydrolase inhibition in deoxyadenosine-treated human T-lymphoblasts and resting peripheral blood lymphocytes.

R. Kefford, R. Fox, M. A. Helmer, 1982, Cancer research.

Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer.

J. Rasko, C. Begley, J. Zalcberg, 1997, Blood.

Molecular cloning of a novel human gene (D11S4896E) at chromosomal region 11p15.5.

C. Begley, R. Fox, N. Parker, 1996, Genomics.

Primary cerebral lymphoma: an argument for the use of adjunctive systemic chemotherapy.

M. Rosenthal, M. Green, W. Sheridan, 1993, Australian and New Zealand Journal of Surgery.

DNA damage, poly (ADP-ribosyl)ation and apoptotic cell death as a potential common pathway of cytotoxic drug action.

D. Marks, R. Fox, 1991, Biochemical pharmacology.

Hyaluronan-Irinotecan improves progression-free survival in 5-fluorouracil refractory patients with metastatic colorectal cancer: a randomized phase II trial

P. Gibbs, V. Ganju, N. Tebbutt, 2010, Cancer Chemotherapy and Pharmacology.

A Pilot Human Evaluation of a Formulation of Irinotecan and Hyaluronic Acid in 5-Fluorouracil-Refractory Metastatic Colorectal Cancer Patients

P. Gibbs, M. Michael, R. Jennens, 2008, Chemotherapy.

Oral chlorambucil for extranodal, marginal zone, B-cell lymphoma of mucosa-associated lymphoid tissue of the orbit.

N. Cheung, P. Mckelvie, R. Fox, 2006, Ophthalmology.

Fludarabine and mitoxantrone: effective and well-tolerated salvage therapy in relapsed indolent lymphoproliferative disorders.

J. Szer, J. Seymour, R. Fox, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Delay by internists in obtaining diagnostic biopsies in patients with suspected cancer.

S. Farag, M. Green, W. Sheridan, 1992, Annals of internal medicine.

Enhanced levels and enhanced clonogenic capacity of blood progenitor cells following administration of stem cell factor plus granulocyte colony-stimulating factor to humans.

C. Begley, C. Begley, J. Cebon, 1997, Blood.

KRN8602 (MX2-hydrochloride): an active new agent for the treatment of recurrent high-grade glioma.

A. Kaye, M. Green, J. Hill, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

KRN8602 ( MX2-Hydrochlori de): A n A ctive N ew A gent f or t he Treatment o f R ecurrent H igh-Grade G lioma

A. Kaye, John S. Hill, Michael D. Green, 1999 .

Phase I and pharmacokinetic study of KRN8602 alone and with filgrastim in patients with advanced cancer.

C. Alt, A. Kaye, D. Morgan, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer

C. Begley, J. Rasko, C. Begley, 1996, The Lancet.

Human gene for the large subunit of ribonucleotide reductase (RRM1): functional analysis of the promoter.

C. Begley, R. Fox, N. Parker, 1995, Genomics.

Ribonucleotide reductase M1 subunit in cellular proliferation, quiescence, and differentiation.

G. Mann, E. Musgrove, R. Fox, 1988, Cancer research.

Lipid domain in cancer cell plasma membrane shown by 1H NMR to be similar to a lipoprotein

C. Mountford, K. Holmes, R. Fox, 1985, FEBS letters.

Ecto-adenosine triphosphatase deficiency in cultured human T and null leukemic lymphocytes. A biochemical basis for thymidine sensitivity.

M. Tattersall, R. Fox, E. Tripp, 1981, The Journal of clinical investigation.

Deoxyadenosine induced G1 phase arrest in leukemic T cells.

I. Taylor, R. Fox, E. Tripp, 1984, Advances in experimental medicine and biology.

Systemic Lupus Erythematosus

R. Fox, 2013 .

Recombinant alpha-2b interferon in patients with malignant carcinoid tumour.

M. Green, G. Lieschke, W. Sheridan, 1991, Australian and New Zealand journal of medicine.

Phase I and Pharmacokinetic Evaluation of Intravenous Hyaluronic Acid in Combination with Doxorubicin or 5-Fluorouracil

P. Gibbs, P. Heldin, M. Rosenthal, 2005, Chemotherapy.

Colony-Stimulating Factors

R. Fox, Prof. R. M. Fox, 2012, PharmacoEconomics.

Multicycle high-dose chemotherapy and filgrastim-mobilized peripheral-blood progenitor cells in women with high-risk stage II or III breast cancer: five-year follow-up.

C. Begley, J. Collins, J. Szer, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combination chemotherapy as single modality therapy for stage IE and IIE thyroid lymphoma

P. Leedman, F. Martin, W. Sheridan, 1990, The Medical journal of Australia.

Quantitation of G0 and G1 phase cells in primary carcinomas. Antibody to M1 subunit of ribonucleotide reductase shows G1 phase restriction point block.

P. Bhathal, R. Fox, D. Tay, 1991, The Journal of clinical investigation.

Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy.

C. Begley, J. Szer, L. To, 1992, Lancet.

Administration of pegylated recombinant human megakaryocyte growth and development factor to humans stimulates the production of functional platelets that show no evidence of in vivo activation.

C. Begley, J. Rasko, C. Begley, 1996, Blood.

Enhancement of platelet recovery after myelosuppressive chemotherapy by recombinant human megakaryocyte growth and development factor in patients with advanced cancer.

C. Begley, J. Zalcberg, I. Davis, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Enhancement o f P latelet R ecovery A fter M yelosuppressive Chemotherapy b y R ecombinant H uman M egakaryocyte Growth a nd D evelopment F actor i n P atients With A dvanced C ancer

Michael R. Green, C. Begley, J. Zalcberg, 2000 .

Multicycle H igh-Dose C hemotherapy a nd Filgrastim-Mobilized P eripheral-Blood P rogenitor C ells in W omen W ith H igh-Risk S tage I I o r I II B reast C ancer: Five-Year F ollow-Up

C. Begley, J. Collins, J. Szer, 1999 .

Pharmacokinetics of human granulocyte-macrophage colony-stimulating factor using a sensitive immunoassay.

A. Burgess, P. Dempsey, J. Cebon, 1988, Blood.

Colony stimulating factors: twenty years from discovery to clinical trials.

G. Morstyn, R. Fox, 1988, The Australian and New Zealand journal of surgery.

factor using a sensitive immunoassay Pharmacokinetics of human granulocyte-macrophage colony-stimulating

A. Burgess, P. Dempsey, J. Cebon, 2010 .

Phase I study of intravenously administered bacterially synthesized granulocyte-macrophage colony-stimulating factor and comparison with subcutaneous administration.

A. Burgess, M. Green, G. Lieschke, 1990, Cancer research.

Clinical experience with recombinant human granulocyte colony-stimulating factor and granulocyte macrophage colony-stimulating factor.

J. Cebon, G. Lieschke, W. Sheridan, 1989, Seminars in hematology.

Sequential pure red cell and megakaryocyte aplasia associated with chronic liver disease and ulcerative colitis

R. Fox, F. Firkin, Richard Fox, 1978, American journal of hematology.

Evidence for a New Mechanism of Cytotoxicity of 1-β-d Arabinofuranosylcytosine

R. Fox, D. Woodcock, I. Cooper, 1979 .

Rapid hematopoietic recovery after multicycle high-dose chemotherapy: enhancement of filgrastim-induced progenitor-cell mobilization by recombinant human stem-cell factor.

C. Begley, J. Collins, J. Szer, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mechanism of deoxycytidine rescue of thymidine toxicity in human T-leukemic lymphocytes.

M. Tattersall, R. Fox, E. Tripp, 1980, Cancer research.

G-CSF mobilised progenitor cells in autologous transplantation: in vitro and in vivo aspects.

C. Begley, J. Szer, W. Sheridan, 1992, Journal of nutritional science and vitaminology.

Patients' socioeconomic background: influence on selection of inpatient or domiciliary hospice terminal‐care programmes

P. Komesaroff, R. Fox, Charlie Moss, 1989, The Medical journal of Australia.

G1-phase arrest of cultured human leukemic T-cells induced by deoxyadenosine.

I. Taylor, R. Kefford, R. Fox, 1981, Cancer research.

Changes in deoxynucleoside triphosphate pools induced by inhibitors and modulators of ribonucleotide reductase.

R. Fox, 1985, Pharmacology & therapeutics.

Peripheral Vascular Disease as a Mode of Presentation of Pseudoxanthomaasticum

M. Wahlqvist, R. Fox, I. Favilla, 1977 .

The activities of thymidine metabolising enzymes during the cell cycle of a human lymphocyte cell line LAZ-007 synchronised by centrifugal elutriation.

M. Tattersall, M. Tattersall, R. Fox, 1980, Biochimica et biophysica acta.

Characterization of transformed cells and tumors by proton nuclear magnetic resonance spectroscopy.

R M Fox, C. Mountford, C E Mountford, 1982, Cancer research.

RNA in nascent DNA from cultured human lymphocytes.

R. Fox, M. Goulian, J. Mendelsohn, 1973, Nature: New biology.

Flow cytometric analysis of adenosine analogue lymphocytotoxicity.

I. Taylor, R. Kefford, R. Fox, 1983, Cancer research.

High-resolution proton nuclear magnetic resonance analysis of metastatic cancer cells.

W. Mackinnon, C. Mountford, K. Holmes, 1984, Science.

Biochemical basis for the differential sensitivity of human T- and B-lymphocyte lines to 5-fluorouracil.

R. Fox, A. Piper, 1982, Cancer research.

Cellular immune deficiency in two siblings with hereditary orotic aciduria.

C. Griscelli, A. Durandy, R. Girot, 1983, The New England journal of medicine.

and B-Lymphocyte Lines to 5-Fluorouracil Biochemical Basis for the Differential Sensitivity of Human T-

R. Fox, A. Piper, 2013 .

Sensitivity of leukemic human null lymphocytes to deoxynucleosides.

M. Tattersall, R. Fox, E. Tripp, 1980, Cancer research.

Incorporation of deoxynucleotides into DNA by diethylaminoethyldextran-treated lymphocytes.

R. Fox, M. Goulian, J. F. Mynderse, 1977, Biochemistry.

Allopurinol modulation of fluorouracil toxicity

M. Tattersall, R. Fox, A. Piper, 1981, Cancer Chemotherapy and Pharmacology.

High‐dose chemotherapy with busulphan and cyclophosphamide and bone‐marrow transplantation for drug‐sensitive malignancies in adults: a preliminary report

A. Boyd, Michael D. Green, W. Sheridan, 1989, The Medical journal of Australia.

Terminal incorporation of 2'-deoxyadenosine into polyadenylate segments of polyadenylated RNA in G1-phase-arrested human T-lymphoblasts.

R. Kefford, G. Muscat, P. B. Rowe, 1983, Cancer research.

Deoxyadenosine triphosphate as a mediator of deoxyguanosine toxicity in cultured T lymphoblasts.

G. Mann, R. Fox, 1986, The Journal of clinical investigation.

MALIGNANT HAEMANGIOPERICYTOMA: CASE REPORT AND ULTRASTRUCTURAL STUDY

R. Fox, R. Newland, L. Maxwell, 1978, Pathology.

Filgrastim in Patients with Chemotherapy-Induced Febrile Neutropenia: A Double-Blind, Placebo-Controlled Trial

Max Wolf, Joseph McKendrick, George Morstyn, 1994, Annals of Internal Medicine.

G‐CSF‐mobilized peripheral and autologous bone marrow infusion following high dose chemotherapy

C. Begley, J. Szer, L. To, 1992 .

Commentary on the ASCO and ESMO Evidence-Based Clinical Practice Guidelines for the Use of Hematopoietic Colony-Stimulating Factors

R. Fox, 2004 .

Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy

R. M. Fox, C. Begley, J. Szer, 1992, The Lancet.

Purinogenic lymphocytotoxicity: Clues to a wider chemotherapeutic potential for the adenosine deaminase inhibitors

R. Kefford, R. Fox, 2004, Cancer Chemotherapy and Pharmacology.

Deoxycoformycin‐induced response in chronic lymphocytic leukaemia: deoxyadenosine toxicity in non‐replicating lymphocytes

R. Kefford, R. Fox, 1982, British journal of haematology.

Relative sensitivity of human T cell subsets to deoxyadenosine toxicity.

R. Fox, R. Callard, T. Ewing, 1984, Clinical and experimental immunology.

Diagnostic pathology of lymphoproliferative disorders

David W. Ellis, Michael Eaton, Richard M. Fox, 2005, Pathology.

Phase I and subsequent phase II study of filgrastim (r-met-HuG-CSF) and dose intensified cyclophosphamide plus epirubicin in patients with non-Hodgkin's lymphoma and advanced solid tumors.

J. Zalcberg, M. Green, R. Fox, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

A Phase I and Pharmacokinetic Study of Subcutaneously-Administered Recombinant Human Interleukin-4 (rhuIL-4) in Patients with Advanced Cancer

I. Davis, A. Boyd, Michael D. Green, 2000, Growth factors.

ADJUVANT CHEMOTHERAPY, EARLY BREAST CANCER AND POSITIVE BONE SCAN

R. Fox, N. Adiseshan, 1977, The Medical journal of Australia.

Colony-stimulating factors. Present status and future potential.

R. Fox, 1994, PharmacoEconomics (Auckland).

Adjuvant thoracic radiotherapy in small cell lung cancer: ten-year follow-up of a randomized study

M. Tattersall, M. Rosenthal, R. Fox, 1991 .

Nascent DNA from phytohemagglutinin-stimulated human lymphocytes.

R. Fox, M. Goulian, J. Mendelsohn, 1975, Immunological communications.

Treatment of advanced squamous‐cell carcinoma of the head and neck with a combination of cisplatin, vinblastine, and bleomycin

M. Tattersall, A. Coates, M. Tattersall, 1984, Medical Journal of Australia.

Cardiac effects of high-dose epirubicin and cyclophosphamide in women with poor prognosis breast cancer.

L. To, M. Green, R. Abraham, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Ocular adnexal lymphoproliferative disease: a series of

P. Mckelvie, R. Fox, Alan A McNab DMedSc Franzco, 2001 .

Cisplatin, fludarabine, and cytarabine

J. Szer, J. Seymour, R. Fox, 2002, Cancer.

Marrow proliferation and the appearance of giant neutrophils in response to recombinant human granulocyte colony stimulating factor (rhG‐CSF)

A. Boyd, S. Rockman, G. Morstyn, 1992, British journal of haematology.

Assignment of methylene proton resonances in NMR spectra of embryonic and transformed cells to plasma membrane triglyceride.

P E Wright, R M Fox, P. Wright, 1986, The Journal of biological chemistry.

Pilot study of escalating doses of carboplatin and cyclophosphamide in patients with advanced cancer

Michael D. Green, W. Sheridan, R. Fox, 2004, Cancer Chemotherapy and Pharmacology.

Dose escalation study of carboplatin and cyclophosphamide with filgrastim support: a phase I study.

J. Cebon, M. Green, W. Sheridan, 1998, American journal of clinical oncology.

Plasma membrane lipid composition of vinblastine sensitive and resistant human leukaemic lymphoblasts

W. Mackinnon, C. Mountford, R. Fox, 1988, International journal of cancer.

The Price of Cigarettes

C. Mountford, R. Fox, G. Grossman, 1999, Environmental Health Perspectives.

Peripheral vascular disease as a mode of presentation of pseudoxanthoma elasticum.

M. Wahlqvist, R. Fox, I. Favilla, 1977, Australian and New Zealand journal of medicine.

Effects of bacterially synthesized recombinant human granulocyte-macrophage colony-stimulating factor in patients with advanced malignancy.

A. Burgess, A. Boyd, J. Cebon, 1989, Annals of internal medicine.

EFFECT OF GRANULOCYTE COLONY STIMULATING FACTOR ON NEUTROPENIA INDUCED BY CYTOTOXIC CHEMOTHERAPY

M. Green, W. Sheridan, D. Metcalf, 1988, The Lancet.

Decreased progesterone binding and attenuated progesterone action in cultured human breast carcinoma cells treated with epidermal growth factor.

W. Blattner, J. Nadeau, C. Pui, 1988, Cancer research.

High-resolution proton nuclear magnetic resonance: application to the study of leukaemic lymphocytes.

C. Mountford, R. Fox, P. Gatenby, 1980, British Journal of Cancer.

The Price of Cigarettes

C. Mountford, R. Fox, G. Grossman, 1999, Environmental Health Perspectives.

Surgical biopsy in lymphoma *

R. Fox, M. Eaton, 2005, ANZ journal of surgery.

Diffuse large cell lymphoma: a teaching hospital experience.

M. Green, W. Sheridan, D. Marks, 1989, Australian and New Zealand journal of medicine.

Short communication Pilot study of escalating doses of carboplatin and cyclophosphamide in patients with advanced cancer

Michael R. Green, W. Sheridan, R. Fox, 1992 .

Meta AMSA (m‐AMSA) in Patients with Advanced Ovarian Carcinoma

M. Tattersall, A. Coates, J. Kearsley, 1982, The Australian & New Zealand journal of obstetrics & gynaecology.

Advanced breast cancer: response to high dose oral medroxyprogesterone acetate.

M. Tattersall, D. Hedley, A. Coates, 1984, Australian and New Zealand journal of medicine.

Ecto-adenosine triphosphatase: an enzyme correlating with resistance to deoxynucleoside growth inhibition.

R. Fox, L. C. Wright, G. Reid, 1984, Advances in experimental medicine and biology.